Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.50p +0.07% 3,690.00p 3,640.00p 3,740.00p 3,695.00p 3,690.00p 3,695.00p 2,256 10:19:44
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 175.0 -38.3 16.2 249.4 2,241.13

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
19/9/201715:13(Chi-Med)Hutchinson China Meditech Limited1,011
13/6/201707:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 3,687.50p.
Hutchison China Meditech has a 4 week average price of 3,590p and a 12 week average price of 3,375p.
The 1 year high share price is 4,055p while the 1 year low share price is currently 1,797.50p.
There are currently 60,735,104 shares in issue and the average daily traded volume is 18,452 shares. The market capitalisation of Hutchison China Meditech is £2,241,125,337.60.
nerdofsteel: "What price would you advise buying at?" Any, I mean the share price has grown in excess of 2000% in the last 10 years and we don't have a drug on the market, yet, although our first application has been submitted to the CFDA, so expect launch next year, followed by a number of others. If you look at a P/S of say 14 and a P/E of say 70 (Genmab is a great peer to compare HCM to) you can see Analysts forecasting sales of circa $650m by 2020 which equates to $9,100m mcap or circa £108 per share ish. So if anyone has a long term view like me (8 - 10 yrs) this is a bargain, even at this price IMO
reptile3: I think those who keep an eye on technical analysis would say the share price was bound to visit £36 (or thereabouts), being on a projected line of support before resuming its upward move. If this is correct we should experience a day or two of stability followed by a significant rebound next week to maybe £41 or £42..... IMHO
nimrod22: Looks as if the share price is going to pull back further.......and hopefully have another rally in a couple of weeks
mad foetus: More director buys. I tried a cheeky top up online but none available. Await the inevitable news and a £50 share price over the next couple of months
nerdofsteel: I agree dbadvn although for me price swings are irrelevant as I've been invested and have been building a position for 10 years and will continue for the next 10 years. 2000% in the last 10 years has demonstrated that, over the long term, the Company delivers. I agree with your point about NASDAQ and US Analysts, as that is what is controlling the share price. The London listing is now irrelevant and I can see a time when they de-list as it serves no real purpose at all.
nerdofsteel: Growth over the last 10 years has been astonishing and Simon To is right to state “Chi-Med’;s consistent strategy over the past 16 years has generated considerable shareholder value" - to the tune of 2000% However, I think he is also right to suggest that if you think that is astonishing, you ain't seen nothing yet! The CEO said recently they were working on 2 or 3 big things any one of which will radically change 2017 guidance. That suggests a major Big Pharma licencing deal is on the cards like the recent Beigene/Celgene one announced 2 weeks ago, prompting Beigene's share price to go up 75%
nerdofsteel: "The relative ignorance in the US about the company’s potential makes it a great investment right now" This article offers a great perspective for those looking to invest for the long term, and by that I mean 5 years + And it is the U.S share price that mainly drives the UK share price now, as volumes are usually bigger on NASDAQ
storm8: There is an article in tonight's London Evening Standard confirming the progress Chi Med have made and the Phase III trials of the cancer drug Fruquintinib, and probably one of the drivers for the >3% rise in share price today. I hold and will continue to do so.
nerdofsteel: The LSE share price tanked because the NASDAQ IPO (2 x ADR's per AIM Ordinary share) was priced below what was originally expected, presumably because the Institutions taking up the offer wouldn't pay the full price. The effect was the London share price tanked overnight. Now Institutions are starting to buy on NASDAQ, because they can see exactly how valuable the pipeline is and that this Company is unique in the Biotech space eg. it actually generates cash. The bb is quiet because there are very very few Private Investors, most are instutions (it is Mark Slater's largest holding in his growth fund. CK Hutchison hold 60%. IMO most private Investors do not invest because drug development is a very very long term game. However, after 14 years we have our first drugs coming to the market next year and these will be Blockbusters with peak annual sales potential of $100's millions Looking at the sales forecasts, using standard valuations of P/E, P/S, nett margis etc it is my view we will have a mcap in excess of $10bn within the next 5-10 years
nerdofsteel: Thanks Steeplejack, I noticed that I have a model which uses a range of criteria to value the Company based on blended Biotech and Pharmaceutical averages of P/E, P/S and nett margins, amongst other metrics. Based in what is a very conservative revenue number of $657m, which assumes Savolitinib and Frquinitinib get BT for certain targets and only achieve 50% of forecast peak sales my valuation figures are:- 2020 Revs $657,000,000 EPS $1.56 P/S 10.92 mcap $5,902,845,408 ADR Price $48.66 Ordinary share price £76.63 (2 x ADR) Moving from 2020 towards 2025 and 2030 the figures become even more interesting. The only thing that may hold back some U.S. Institutional Investors is that there's little if any chance of the Company being taken over, unlike small U.S Biotech's that often get a single drug or a couple of drugs to market then get swallowed up by a major player (Baxalta is a great example)
Hutchison China Meditech share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170920 16:49:40